Drugs / Tiagabine
Tiagabine
also known as
Gabitril · Tiagabine Hydrochloride · A-70569-1 · ABBOTT-70569 FREE BASE · ABBOTT-70569 HYDROCHLORIDE · ABBOTT-70569.1 · ABBOTT-70569.HCL · ABBOTT-705691 FREE BASE · +10 more
Small molecule targets SLC6A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GABITRIL | — | 1997-09-30 | fda.gov ↗ |
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01904487 | Apr 2011 → Oct 2013 | alcohol dependence | Rajesh Narendran | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00129298 | Dec 2004 → Apr 2007 | cocaine dependence, opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00086255 | Oct 2002 → Jun 2004 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT00214994 | Jan 2005 → Dec 2006 | anxiety disorder | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00236015 | Nov 2004 → Mar 2006 | anxiety disorder | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00236067 | Oct 2004 → Mar 2006 | generalized anxiety disorder | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00236054 | Oct 2004 → Dec 2005 | generalized anxiety disorder | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00233675 | Aug 2003 → Feb 2005 | generalized anxiety disorder | Cephalon | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT00855738 | May 2007 → Jun 2009 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00174850 | Jul 2004 → May 2005 | anxiety, sexual disorder | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00208741 | Jun 2002 → Nov 2003 | social phobia | Emory University | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT02387710 Comparator | Mar 2015 → Jun 2016 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00218166 Comparator | Aug 2001 → May 2005 | cocaine abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 3 | NCT00179465 Comparator | Nov 2003 → Sep 2026 overdue | schizophrenia | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-03-12 | Impax Laboratories, LLC | Amneal Launches Generic for Gabitril® amneal.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tiagabine | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗10“A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With...” NCT00208741 ↗ “Tiagabine is a Selective GABA Reuptake Inhibitor (SGRI) that is FDA approved to treat certain types of epilepsy.” NCT00174850 ↗ “Triazolam, tiagabine, baclofen” NCT00218166 ↗ |
| Known as | A-70569-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABBOTT-70569 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABBOTT-70569 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABBOTT-70569.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABBOTT-70569.HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABBOTT-705691 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABT-569 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | ABT-569 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | CEP-6671 | “GABITRIL (tiagabine hydrochloride; CEP-6671)” NCT00233675 ↗ |
| Known as | Gabatril | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | Gabitril | “A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With...” NCT00208741 ↗8“After the first PET scan, you will be given an oral dose of tiagabine (Gabitril®), which is a medication approved for the treatment of seizure disorder.” NCT01904487 ↗ “Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction” NCT00174850 ↗ “treatment with tiagabine (Gabitril) during the early course of schizophrenia” NCT00179465 ↗ “GABITRIL (tiagabine hydrochloride; CEP-6671)” NCT00233675 ↗ |
| Known as | NNC-05-0328 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | NNC-050328 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | NO-05-0328 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | NO-050328 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | Tiagabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | Tiagabine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1027 ↗ |
| Known as | Tiagabine Hydrochloride | “A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With...” NCT00208741 ↗1“GABITRIL (tiagabine hydrochloride; CEP-6671)” NCT00233675 ↗ |
| Action | Inhibit | “a GABA transporter GAT-1-specific inhibitor” NCT00179465 ↗1“GABA transporter 1 inhibitor” CHEMBL1027 ↗ |
| Modality | Small molecule | — CHEMBL1027 ↗ |
| Route | Oral | “After the first PET scan, you will be given an oral dose of tiagabine (Gabitril®), which is a medication approved for the treatment of seizure disorder.” NCT01904487 ↗ |
| Target | SLC6A1 | “GABA transporter 1 inhibitor” CHEMBL1027 ↗ |